Bayforest Capital Ltd Purchases New Shares in ICU Medical, Inc. $ICUI

Bayforest Capital Ltd acquired a new position in shares of ICU Medical, Inc. (NASDAQ:ICUI) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,942 shares of the medical instruments supplier’s stock, valued at approximately $257,000.

A number of other large investors have also recently bought and sold shares of the company. Equitable Trust Co. grew its stake in ICU Medical by 59.8% during the second quarter. Equitable Trust Co. now owns 8,538 shares of the medical instruments supplier’s stock worth $1,128,000 after buying an additional 3,196 shares in the last quarter. Verdence Capital Advisors LLC acquired a new stake in ICU Medical during the second quarter worth about $484,000. Johnson Investment Counsel Inc. grew its stake in ICU Medical by 17.7% during the second quarter. Johnson Investment Counsel Inc. now owns 1,699 shares of the medical instruments supplier’s stock worth $225,000 after buying an additional 256 shares in the last quarter. Inspire Investing LLC grew its stake in ICU Medical by 20.0% during the second quarter. Inspire Investing LLC now owns 2,996 shares of the medical instruments supplier’s stock worth $396,000 after buying an additional 499 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in ICU Medical by 17.6% during the second quarter. Blue Trust Inc. now owns 942 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 141 shares in the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have issued reports on ICUI. Raymond James Financial reduced their price objective on shares of ICU Medical from $187.00 to $180.00 and set a “strong-buy” rating on the stock in a research note on Friday, August 8th. Wall Street Zen raised shares of ICU Medical from a “hold” rating to a “buy” rating in a report on Friday, September 5th. Piper Sandler increased their target price on shares of ICU Medical from $145.00 to $153.00 and gave the stock an “overweight” rating in a report on Wednesday, September 10th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of ICU Medical in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $181.00.

Insider Activity at ICU Medical

In other news, CEO Vivek Jain purchased 21,929 shares of the stock in a transaction on Thursday, August 14th. The stock was purchased at an average price of $112.84 per share, for a total transaction of $2,474,468.36. Following the acquisition, the chief executive officer owned 130,149 shares in the company, valued at $14,686,013.16. This trade represents a 20.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David C. Greenberg purchased 1,200 shares of the stock in a transaction on Wednesday, August 27th. The shares were purchased at an average price of $126.42 per share, with a total value of $151,704.00. Following the acquisition, the director owned 7,960 shares in the company, valued at approximately $1,006,303.20. The trade was a 17.75% increase in their position. The disclosure for this purchase can be found here. 1.50% of the stock is currently owned by company insiders.

ICU Medical Stock Up 0.2%

Shares of NASDAQ ICUI opened at $116.49 on Friday. The company has a 50 day simple moving average of $123.34 and a 200 day simple moving average of $130.20. The firm has a market cap of $2.88 billion, a PE ratio of -76.64 and a beta of 0.83. ICU Medical, Inc. has a 1 year low of $107.00 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.44 and a quick ratio of 1.17.

ICU Medical (NASDAQ:ICUI) last released its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $2.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.44 by $0.66. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The firm had revenue of $543.57 million during the quarter, compared to analyst estimates of $543.33 million. During the same quarter last year, the business earned $1.56 EPS. The company’s revenue was down 8.0% compared to the same quarter last year. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. On average, research analysts forecast that ICU Medical, Inc. will post 4.11 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.